glp-1 receptor agonist with dpp-4 inhibitor combination not recommended versus and kidney and cardiovascular outcomes in clinical practice in type-2 diabetes Insights into the Roles of
Description
The ACC recommends GLP-1R agonists for cardiovascular risk reduction in patients with T2DM and established ASCVD [114]
San Diego Business Journal
doi: 10.1016/j.neuroscience.2015.05.023 29 RojasMChavez-CastilloMBautistaJOrtegaANavaMSalazarJet al
This matters because millions of people sit in a gray zone
